Royalty Pharma (RPRX) Net Income towards Common Stockholders (QoQ) (2019 - 2026)
Royalty Pharma (RPRX) Net Income towards Common Stockholders (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Royalty Pharma | 25.71 Bn | 25.10 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.56% |
| Dec 31, 2025 | -19.88% |
| Sep 30, 2025 | 390.11% |
| Jun 30, 2025 | -79.14% |
| Mar 31, 2025 | 29.93% |
| Dec 31, 2024 | -58.54% |
| Sep 30, 2024 | 314.84% |
| Jun 30, 2024 | 4,648.96% |
| Mar 31, 2024 | -100.60% |
| Dec 31, 2023 | 487.81% |
| Sep 30, 2023 | -65.25% |
| Jun 30, 2023 | -30.99% |
| Mar 31, 2023 | 183.45% |
| Dec 31, 2022 | -376.77% |
| Sep 30, 2022 | -55.16% |
| Jun 30, 2022 | 283.81% |
| Mar 31, 2022 | 138.64% |
| Dec 31, 2021 | -75.80% |
| Sep 30, 2021 | -72.51% |
| Jun 30, 2021 | 407.46% |